CoChat

Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 y of age in at least three continents. Choroidal neovascularization (CNV) is the process by which abnormal blood vessels develop underneath the retina. CNV develops in 10% of patients with AMD but accounts for up to 90% of the blindness from AMD. Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response, which has been shown to promote tumor growth and support atherosclerotic plaque formation, is thought to stimulate aberrant angiogenesis in blinding eye diseases. The current theory is that macrophage infiltration promotes the development of neovascularization in CNV. METHODS AND FINDINGS: We examined the role of macrophages in a mouse model of CNV. IL-10(-/-) mice, which have increased inflammation in response to diverse stimuli, have significantly reduced CNV with increased macrophage infiltrates compared to wild type. Prevention of macrophage entry into the eye promoted neovascularization while direct injection of macrophages significantly inhibited CNV. Inhibition by macrophages was mediated by the TNF family death molecule Fas ligand (CD95-ligand). CONCLUSIONS: Immune vascular interactions can be highly complex. Normal macrophage function is critical in controlling pathologic neovascularization in the eye. IL-10 regulates macrophage activity in the eye and is an attractive therapeutic target in order to suppress or inhibit CNV in AMD that can otherwise lead to blindness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0030310

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 IL-10 and Neovascularization (CNV) (A and B) CNV was induced in IL-10 −/− (volume of the neovascular complex: 829.6 ± 225.7 μm3) and B6 (IL-10 +/+; 8,830.7 ± 1,130.3 μm3) mice (A) and B6 mice injected on days 0, 3, and 5 with anti-IL-10 (10,115.3 ± 850.5 μm3) or isotype control antibody (IgG2b; 33,602.3 ± 317.4 μm3) (B). Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test performed as described [17,18]. (C and D) Seven days following laser treatment, the volumes of the neovascular complexes (green) were determined by confocal microscopy. Shown is representative CNV in a B6 eye (C) and an IL-10 −/− eye (D).
Figure 1 IL-10 and Neovascularization (CNV) (A and B) CNV was induced in IL-10 −/− (volume of the neovascular complex: 829.6 ± 225.7 μm3) and B6 (IL-10 +/+; 8,830.7 ± 1,130.3 μm3) mice (A) and B6 mice injected on days 0, 3, and 5 with anti-IL-10 (10,115.3 ± 850.5 μm3) or isotype control antibody (IgG2b; 33,602.3 ± 317.4 μm3) (B). Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test performed as described [17,18]. (C and D) Seven days following laser treatment, the volumes of the neovascular complexes (green) were determined by confocal microscopy. Shown is representative CNV in a B6 eye (C) and an IL-10 −/− eye (D).CC BY · PubMed Central
Figure 2 Cellular Infiltrates in CNV Lesions (A–C) On day 7 following laser treatment, whole mount stains were performed to determine the cells present in the area of the neovascular complex. Stains for CD11b were performed on (A) B6, (B) IL-10 −/−, and (C) B6 mice treated with neutralizing anti-IL-10. Images were take by confocal microscopy (magnification 200×) centered on the laser lesion. (D) The number of CD11b+ cells per lesion was counted (200× high-power field centered on the laser lesion) (B6, 6.3 ± 0.9; IL10 −/−, 22.6 ± 2.1; B6 + anti-IL10, 22.5 ± 2.5). Asterisks indicate values significantly different from control. (E) Dual staining was performed on day 7 following laser treatment using FITC-conjugated anti-CD11b (green) and PE-conjugated anti-F4/80 (red) (magnification 400×).
Figure 2 Cellular Infiltrates in CNV Lesions (A–C) On day 7 following laser treatment, whole mount stains were performed to determine the cells present in the area of the neovascular complex. Stains for CD11b were performed on (A) B6, (B) IL-10 −/−, and (C) B6 mice treated with neutralizing anti-IL-10. Images were take by confocal microscopy (magnification 200×) centered on the laser lesion. (D) The number of CD11b+ cells per lesion was counted (200× high-power field centered on the laser lesion) (B6, 6.3 ± 0.9; IL10 −/−, 22.6 ± 2.1; B6 + anti-IL10, 22.5 ± 2.5). Asterisks indicate values significantly different from control. (E) Dual staining was performed on day 7 following laser treatment using FITC-conjugated anti-CD11b (green) and PE-conjugated anti-F4/80 (red) (magnification 400×).CC BY · PubMed Central
Figure 3 Inhibition of Macrophage Infiltration Promotes CNV (A) IL-10 −/− mice were injected with anti-CD11b (volume of the neovascular complex: 12,903.1 ± 2,171.3 μm3), anti-F4/80 (9,977.3 ± 1,572.7 μm3), or control IgG (2,262.3 ± 313.4 μm3) on days −1, 0, and +1. CNV volumes were determined on day 7. (B) IL-10 −/− mice were injected in the vitreous with PBS (1,394 ± 382.4 μm3) or 100 ng of rIL-10 on day 0 (the day of laser treatment; 4,033.6 ± 1,026.5 μm3) or day 3 (6,949.8 ± 1,475.5 μm3). (C and D) Cross-sections of the retinas of a control littermate (C) and a VMD2-IL-10 Tg mouse (D) stained with anti-IL-10 and examined by confocal microscopy. (E) Hematoxylin and eosin staining of the retina of a VMD2-IL-10 Tg mouse (magnification 200×). (F) VMD2-IL-10 Tg mice (24,428.6 ± 4,360.7 μm3) and littermate controls (6,830.1 ± 1,324.9 μm3) were subjected to laser treatment and CNV volumes were determined on day 7. Asterisks indicate values significantly different from control; p-values are given in parentheses.
Figure 3 Inhibition of Macrophage Infiltration Promotes CNV (A) IL-10 −/− mice were injected with anti-CD11b (volume of the neovascular complex: 12,903.1 ± 2,171.3 μm3), anti-F4/80 (9,977.3 ± 1,572.7 μm3), or control IgG (2,262.3 ± 313.4 μm3) on days −1, 0, and +1. CNV volumes were determined on day 7. (B) IL-10 −/− mice were injected in the vitreous with PBS (1,394 ± 382.4 μm3) or 100 ng of rIL-10 on day 0 (the day of laser treatment; 4,033.6 ± 1,026.5 μm3) or day 3 (6,949.8 ± 1,475.5 μm3). (C and D) Cross-sections of the retinas of a control littermate (C) and a VMD2-IL-10 Tg mouse (D) stained with anti-IL-10 and examined by confocal microscopy. (E) Hematoxylin and eosin staining of the retina of a VMD2-IL-10 Tg mouse (magnification 200×). (F) VMD2-IL-10 Tg mice (24,428.6 ± 4,360.7 μm3) and littermate controls (6,830.1 ± 1,324.9 μm3) were subjected to laser treatment and CNV volumes were determined on day 7. Asterisks indicate values significantly different from control; p-values are given in parentheses.CC BY · PubMed Central
Figure 4 Injection of Macrophages Inhibits CNV Cells obtained from bone marrow (BM) cultures (A) or spleen (B) were purified by magnetic beads and injected into the vitreous cavity on the day of laser treatment. Seven days later, the volume of the neovascular complex was determined by confocal microscopy. Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test. (A) Volume of the neovascular complex for injection of PBS (14,470.9 ± 1,636.4 μm3), CD11b cells—1 × 105 cells (2,431.2 ± 551.3 μm3), and CD11b cells—5 × 105 cells (5,274.2 ± 772.5 μm3). (B) Volume of the neovascular complex for injection of PBS (12,857.9 ± 1,094.9 μm3), CD3 cells (14,960.5 ± 2,502.0 μm3), CD11b cells (4,135.1 ± 714.4 μm3), and CD11c cells (15,063.3 ± 1,982.4 μm3).
Figure 4 Injection of Macrophages Inhibits CNV Cells obtained from bone marrow (BM) cultures (A) or spleen (B) were purified by magnetic beads and injected into the vitreous cavity on the day of laser treatment. Seven days later, the volume of the neovascular complex was determined by confocal microscopy. Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test. (A) Volume of the neovascular complex for injection of PBS (14,470.9 ± 1,636.4 μm3), CD11b cells—1 × 105 cells (2,431.2 ± 551.3 μm3), and CD11b cells—5 × 105 cells (5,274.2 ± 772.5 μm3). (B) Volume of the neovascular complex for injection of PBS (12,857.9 ± 1,094.9 μm3), CD3 cells (14,960.5 ± 2,502.0 μm3), CD11b cells (4,135.1 ± 714.4 μm3), and CD11c cells (15,063.3 ± 1,982.4 μm3).CC BY · PubMed Central
Figure 5 Macrophages Inhibit CNV via CD95L (A) CD11b+ cells from B6, B6-lpr, and B6-gld mice were purified from spleen, and 1 × 105 cells were injected into the vitreous cavity on the day of laser induction of CNV. Seven days later, the volume of the neovascular complex was determined by confocal microscopy for PBS (11,786.4 ± 1,907.3 μm3), B6 (2,084.6 ± 874.8 μm3), gld (15,824.9 ± 1,483.6 μm3), and lpr (5,443.9 ± 542.1 μm3). Asterisks indicate values significantly different from control. (B) Purified CD11b+ cells were cultured overnight with LPS or necrotic retina and tested for killing against L1210-Fas. (C) The expression of CD95L in CD11b cells was determined by flow cytometry following overnight culture with LPS (dotted line) or necrotic retina (solid line). The line with shading underneath represents untreated cells.
Figure 5 Macrophages Inhibit CNV via CD95L (A) CD11b+ cells from B6, B6-lpr, and B6-gld mice were purified from spleen, and 1 × 105 cells were injected into the vitreous cavity on the day of laser induction of CNV. Seven days later, the volume of the neovascular complex was determined by confocal microscopy for PBS (11,786.4 ± 1,907.3 μm3), B6 (2,084.6 ± 874.8 μm3), gld (15,824.9 ± 1,483.6 μm3), and lpr (5,443.9 ± 542.1 μm3). Asterisks indicate values significantly different from control. (B) Purified CD11b+ cells were cultured overnight with LPS or necrotic retina and tested for killing against L1210-Fas. (C) The expression of CD95L in CD11b cells was determined by flow cytometry following overnight culture with LPS (dotted line) or necrotic retina (solid line). The line with shading underneath represents untreated cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 42

  1. Nakao, 2005, J Clin Invest, 115, 2979
  2. Taylor, 2005, Annu Rev Immunol, 23, 901
  3. Hansson, 2005, N Engl J Med, 352, 1685
  4. Sakurai, 2003, Invest Ophthalmol Vis Sci, 44, 3578
  5. Espinosa-Heidmann, 2003, Invest Ophthalmol Vis Sci, 44, 3586
  6. van Leeuwen, 2003, Eur J Epidemiol, 18, 845
  7. Klein, 2004, Am J Ophthalmol, 137, 486
  8. Hebert, 2003, Arch Neurol, 60, 1119
  9. Edwards, 2005, Science, 308, 421
  10. Hageman, 2005, Proc Natl Acad Sci U S A, 102, 7227
  11. Haines, 2005, Science, 308, 419
  12. Klein, 2005, Science, 308, 385
  13. Ambati, 2003, Nat Med, 9, 1390
  14. Lobov, 2005, Nature, 437, 417
  15. Bressler, 2001, Arch Ophthalmol, 119, 198
  16. Gragoudas, 2004, N Engl J Med, 351, 2805
  17. Kaplan, 1999, Nat Med, 5, 292
  18. Apte, 2004, Invest Ophthalmol Vis Sci, 45, 4491
  19. Miller, 1995, Arch Ophthalmol, 113, 810
  20. Adamis, 1996, Arch Ophthalmol, 114, 66
  21. Mori, 2002, Invest Ophthalmol Vis Sci, 43, 1994
  22. Campochiaro, 2006, Hum Gene Ther, 17, 167
  23. Ferguson, 1994, J Exp Med, 179, 1597
  24. Inaba, 1992, J Exp Med, 176, 1693
  25. Marmorstein, 2000, Proc Natl Acad Sci U S A, 97, 12758
  26. Wiley, 2001, Immunity, 15, 837
  27. Moore, 2001, Annu Rev Immunol, 19, 683
  28. Gordon, 1995, J Neuroimmunol, 62, 153
  29. Brown, 1999, J Immunol, 162, 480
  30. Diegelmann, 2004, Front Biosci, 9, 283
  31. Park, 2004, Am J Surg, 187, 11S
  32. Friedman, 2004, Arch Ophthalmol, 122, 564
  33. VanNewkirk, 2000, Ophthalmology, 107, 2203
  34. Bonastre, 2002, Eur J Health Econ, 3, 94
  35. Miskala, 2004, Arch Ophthalmol, 122, 758
  36. Papadimitriou, 2000, J Drug Target, 8, 335
  37. Krasnici, 2003, Int J Cancer, 105, 561
  38. Penfold, 2001, Prog Retin Eye Res, 20, 385
  39. Grossniklaus, 2005, Arch Ophthalmol, 123, 914
  40. Grossniklaus, 2006, Am J Ophthalmol, 141, 93
  41. Kuo, 2000, Int Ophthalmol Clin, 40, 111
  42. Gomez, 2005, Curr Opin Immunol, 17, 457

Cited by

See all 249

Metadata

Authors
Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A.
Affiliations
Washington University in St. Louis (US)
Corresponding author
  • Apte, Rajendra S
  • Ferguson, Thomas A
Venue
PLoS Medicine
Published
2006-08-15
Volume
3
Issue
8
Pages
e310
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2000383031
Cited by
249
References
45
Citations by year
2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 18 · 2019: 11 · 2018: 19 · 2017: 10 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 19 · 2012: 12
FWCI
9.40
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Research to Prevent Blindness
  • National Institutes of Health (5p60dk020579-35, 5r01ey008972-07, DK20579, P60-DK-20579, 5 P60 DK20579, EY06765)
  • National Eye Institute (EY08972, EY 12826, K08EY016139, R01EY012826, F32EY006765, EY06765, R01EY006765)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5P60 DK20579, P60-DK-020579)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
age-related macular degeneration, choroidal neovascularization, macrophages, IL-10, Fas ligand, angiogenesis, choroidal inflammation, macrophage infiltration, therapeutic target
MeSH terms
Aging, Animals, Disease Models, Animal, Injections, Macrophages, Macular Degeneration, Mice, Inbred C57BL, Mice, Transgenic, Molecular Sequence Data, Retina, Interleukin-10, Cell Death, Choroidal Neovascularization, Mice, Fas Ligand Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1371/journal.pmed.0030310
The paper
Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A. (2006). Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0030310

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.